Pacific Biosciences of California, Inc. (PACB) Free cash flow 2016–2025
Pacific Biosciences of California, Inc. (PACB) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$113.9MFY2025 · since FY2016: -$76.1M → -$113.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$113.9M | +46.3% |
| FY2024 | -$212.2M | +20.8% |
| FY2023 | -$268.0M | +4.3% |
| FY2022 | -$280.0M | -139.1% |
| FY2021 | -$117.1M | -734.3% |
| FY2020 | $18.5M | +122.8% |
| FY2019 | -$81.1M | -18.8% |
| FY2018 | -$68.3M | +12.4% |
| FY2017 | -$78.0M | -2.4% |
| FY2016 | -$76.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More PACB financial trends
PACB RevenuePACB Net incomePACB Net marginPACB Gross profitPACB Gross marginPACB Operating incomePACB Operating marginPACB Operating cash flowPACB Capital expendituresPACB Return on equityPACB Stock buybacksPACB Dividends paidPACB Total assetsPACB Total liabilitiesPACB Shareholders’ equityPACB overview →